We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Global Spinal Muscular Atrophy Market Size Share Forecast 2025




 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Overview:

Spinal muscular atrophy is a type of degenerative neurological disorder that affects the nervous system and the voluntary skeletal muscle. It is a common genetic disease characterized by muscular wasting in the motor nerves that are responsible for the movements. This disease can affect either one or more of the three main spinal cord sections. This disease is hereditary and typically begins in childhood and progresses through adulthood.

Growing awareness regarding rare disease and increasing initiatives to improve treatment options for SMA is projected to augment growth of the spinal muscular atrophy market. For example, the enactment of the Orphan Drug Act, 1983 in the U.S., and a similar act for orphan medicinal products in the EU has increased the importance of research activities for the management of rare diseases. Similarly, in 2017, the U.S. FDA approved an orphan drug license to RG7916, a joint development program by Roche, SMA Foundation, and PTC Therapeutics for the treatment of spinal muscular atrophy. Moreover, key players are heavily investing in R & D for the development of a curative treatment which is further anticipated to foster growth of the market.

North America is expected to gain significant growth over the forecast period and this is attributed to the increasing regulatory approval for the drug to treat spinal muscular atrophy in the region. For instance, in August 2020, the U.S. Food and Drug Administration approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. This is the second drug and the first oral drug approved to treat this disease.

Key Developments:

  1. In July 2021, Roche has launched prescription medicine Evrysdi in India, which is used for the treatment of spinal muscular atrophy (SMA) in adults, children aged 2 months and older
  2. In May 2019, AveXis, a Novartis company, announced the US Food and Drug Administration (FDA) has approved Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
  3. In August 2021, Chugai Pharmaceutical Co., Ltd. announced that it launched Evrysdi® Dry Syrup 60 mg (generic name: risdiplam) for the treatment of spinal muscular atrophy (SMA)

Key features of the study:

  • This report provides in-depth analysis of spinal muscular atrophy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global spinal muscular atrophy market based on the following parameters – company overview, financial performance, product portfolio, market presence, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.
    Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global spinal muscular atrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the spinal muscular atrophy market

Detailed Segmentation:

Global Spinal Muscular Atrophy Market, By Disease Type:

Type I
Type II
Type III
Type IV

Global Spinal Muscular Atrophy Market, By Treatment:

Gene Therapy
Drugs

Global Spinal Muscular Atrophy Market, By Age:

Infant
Adult

Global Spinal Muscular Atrophy Market, By Geography:

North America

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

U.S.
Canada


Latin America

By Disease Type:

Type I
Type II
Type III
Type IV


By Treatment:

Gene Therapy
Drugs


By Age:

Infant
Adult


By Country:

Brazil
Mexico
Argentina
Rest of Latin America


Europe

By Disease Type:

Type I
Type II
Type III
Type IV


By Treatment:

Gene Therapy
Drugs


By Age:

Infant
Adult


By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe


Asia Pacific

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs


By Age:

Infant
Adult

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific


Middle East

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

GCC
Israel
Rest of Middle East


Africa

By Disease Type:

Type I
Type II
Type III
Type IV

By Treatment:

Gene Therapy
Drugs

By Age:

Infant
Adult

By Country:

Central Africa
South Africa
North Africa


Company Profiles

Biogen*

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Cytokinetics, Inc.
F. Hoffmann-La Roche
Pfizer Inc.
Novartis AG
Ionis Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Disease Type
o Market Snippet, By Treatment
o Market Snippet, By Age
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Market Trends
o Pricing Analysis
o Clinical Trials For Spinal Muscular Atrophy
o Regulatory Landscape
o Reimbursement Scenario
o Pipeline Analysis
o Epidemiology
o PEST Analysis
4. Global Spinal Muscular Atrophy Market, By Disease Type, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Type I
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Type II
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Type III
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Type IV
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
5. Global Spinal Muscular Atrophy Market, By Treatment, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Gene Therapy
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Drugs
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
6. Global Spinal Muscular Atrophy Market, By Age, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Infant
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Adult
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
7. Global Spinal Muscular Atrophy Market, By Region, 2016 - 2026, (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o North America
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o U.S.
o Canada
o Latin America
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o GCC
o Israel
o Rest of Middle East
o Africa
o Market Size and Forecast, By Disease Type, 2016-2026, (US$ Million)
o Market Size and Forecast, By Treatment, 2016-2026, (US$ Million)
o Market Size and Forecast, By Age, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
o South Africa
o Central Africa
o North Africa
8. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o Biogen*
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Cytokinetics, Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o F. Hoffmann-La Roche
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Pfizer Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Novartis AG
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Ionis Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Key Highlights
o Financial Overview
o Market Strategy
o Analyst Views
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 32 market data tables and 26 figures on "Spinal Muscular Atrophy Market - Global forecast to 2026".

 



Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.